SCHEMBL30647300

CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O

nearest known ligand 0.57

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	KISS1R	Q969F8	3/20	0.57

▸	GLP1R	P43220	14/20	0.57

▸	GIPR	P48546	14/20	0.57

▸	NPY1R	P25929	1/20	0.56

▸	NPY2R	P49146	1/20	0.56

▸	NPY4R	P50391	1/20	0.56

▸	NPY5R	Q15761	1/20	0.56

▸	CALCA	P06881	1/20	0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30647301	0.97	KISS1R (0.57)	KISS1RGLP1RGIPRNPY1RNPY2R
SCHEMBL30647306	0.89	GLP1R (0.68)	GLP1RGIPR
SCHEMBL30490787	0.87	CALCA (0.57)	GLP1RGIPRCALCA
SCHEMBL30647302	0.87	GLP1R (0.66)	GLP1RGIPR
SCHEMBL30647298	0.86	GLP1R (0.68)	GLP1RGIPR
SCHEMBL31058456	0.86	C5AR1 (0.56)	GLP1RGIPR
SCHEMBL30647299	0.86	GLP1R (0.67)	GLP1RGIPR
SCHEMBL30644036	0.86	GLP1R (0.63)	GLP1RGIPR
SCHEMBL31119468	0.86	C5AR1 (0.56)	GLP1RGIPRCALCA
SCHEMBL31119461	0.86	C5AR1 (0.56)	GLP1RGIPRCALCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230364194-A1	GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis	SHENZHEN TURIER BIOTECH CO., LTD. (CN)	2023-11-16	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230364194-A1	GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis	GLP1R, GCGR, GIPR	KISS1R 156/4885GLP1R 1/4885GIPR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.